Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
View in:
PubMed
subject areas
Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Deoxycytidine
Disease Progression
Disease-Free Survival
Female
Humans
Liver Neoplasms
Lung Neoplasms
Male
Middle Aged
Pancreatic Neoplasms
Peritoneal Neoplasms
Survival Rate
Treatment Outcome
Vascular Endothelial Growth Factor A
authors with profiles
Hedy Kindler
Mark Kozloff
Abraham H. Dachman
Walter M. Stadler
Everett E. Vokes
Theodore Karrison